Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Pharmacol. 2011 Dec 5;671(1-3):128-32. doi: 10.1016/j.ejphar.2011.09.163. Epub 2011 Sep 24.

Naringenin suppresses the production of thymic stromal lymphopoietin through the blockade of RIP2 and caspase-1 signal cascade in mast cells.

Author information

  • 1Department of Pharmacology, College of Oriental Medicine, Institute of Oriental Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea.

Abstract

Thymic stromal lymphopoietin (TSLP) plays a critical role in allergic diseases such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. Naringenin has various effects such as anti-atherogenic, anti-oxidant, and anti-inflammatory effects. However, the effect of naringenin on the production of TSLP has not been clarified. Thus, we investigated how naringenin inhibits the production of TSLP in the human mast cell line (HMC-1) cells. Naringenin inhibited the production and mRNA expression of TSLP in HMC-1 cells. The maximal inhibition rate of TSLP production by naringenin (100 μM) was 62.27 ± 10.79%. Naringenin also inhibited the nuclear factor-κB luciferase activity induced by phorbol myristate acetate plus A23187. In the activated HMC-1 cells, the activations of receptor-interacting protein (RIP)2 and caspase-1 were increased, whereas the activations of RIP2 and caspase-1 were decreased by pretreatment with naringenin. These results suggest that naringenin can be used to treat inflammatory and atopic diseases through the inhibition of TSLP.

Copyright © 2011 Elsevier B.V. All rights reserved.

PMID:
21963452
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk